Creative Planning’s Oncternal Therapeutics ONCT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
– Sell
-1,966
Closed -$21.1K – 3044
2023
Q4
$21.1K Hold
1,966
– – ﹤0.01% 2695
2023
Q3
$11.8K Hold
1,966
– – ﹤0.01% 2639
2023
Q2
$13.6K Hold
1,966
– – ﹤0.01% 2528
2023
Q1
$30.9K Hold
1,966
– – ﹤0.01% 2383
2022
Q4
$39.3K Sell
1,966
-6
-0.3% -$119 ﹤0.01% 2255
2022
Q3
$35K Hold
1,972
– – ﹤0.01% 2143
2022
Q2
$44K Buy
1,972
+6
+0.3% +$134 ﹤0.01% 2070
2022
Q1
$55K Sell
1,966
-6
-0.3% -$218 ﹤0.01% 2052
2021
Q4
$90K Sell
1,972
-230
-10% -$15.5K ﹤0.01% 1963
2021
Q3
$184K Buy
2,202
+1,047
+91% +$86.6K ﹤0.01% 1876
2021
Q2
$110K Sell
1,155
-2,327
-67% -$276K ﹤0.01% 1862
2021
Q1
$579K Sell
3,482
-2,054
-37% -$272K ﹤0.01% 1341
2020
Q4
$543K Sell
5,536
-18,851
-77% -$1.19M ﹤0.01% 1267
2020
Q3
$829K Hold
24,387
– – ﹤0.01% 883
2020
Q2
$1.38M Hold
24,387
– – ﹤0.01% 630
2020
Q1
$1.43M Buy
24,387
+515
+2% +$38.4K 0.01% 530
2019
Q4
$1.89M Hold
23,872
– – 0.01% 533
2019
Q3
$2.39M Buy
+23,872
New +$2.44M 0.01% 442
2018
Q4
– Sell
-238
Closed -$52K – 2147
2018
Q3
$52K Buy
+238
New +$571K ﹤0.01% 1873
2017
Q1
– Sell
-3
Closed -$2K – 4968
2016
Q4
$2K Buy
3
+2
+200% +$2.14K ﹤0.01% 4328
2016
Q3
$1K Sell
1
-4
-80% -$3.49K ﹤0.01% 4469
2016
Q2
$4K Buy
5
+4
+400% +$3.74K ﹤0.01% 3794
2016
Q1
$1K Hold
1
– – ﹤0.01% 4199
2015
Q4
$1K Hold
1
– – ﹤0.01% 4274
2015
Q3
$1K Buy
+1
New +$1.46K ﹤0.01% 4177
2014
Q3
– Sell
-3
Closed -$5K – 4197
2014
Q2
$5K Buy
+3
New +$5.94K ﹤0.01% 3249

Other funds holding ONCT

Creative Planning's ONCT Position: Q1 2024 in Review

Creative Planning sold out of Oncternal Therapeutics (ONCT) in Q1 2024, closing a stake of 1,966 shares — an estimated $21.1K sold.

Creative Planning first reported a position in ONCT in Q2 2014 and held it in 26 quarters. The position peaked at $2.39M in Q3 2019. 24 funds tracked by Wall St. Rank hold ONCT as of Q1 2024.

  • Creative Planning reported no remaining Oncternal Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Creative Planning sold 1,966 Oncternal Therapeutics shares in Q1 2024, an estimated $21.1K.
  • Creative Planning first reported a position in Oncternal Therapeutics in Q2 2014 and held it in 26 quarters.
  • Creative Planning's Oncternal Therapeutics position peaked at $2.39M in Q3 2019.
  • 24 funds tracked by Wall St. Rank held Oncternal Therapeutics as of Q1 2024.

Based on Creative Planning's 13F filing for Q1 2024, filed 13 May 2024.